Evidence map›Paper›PMID 24900431›Full record

ArticleACS medicinal chemistry letters2012

Synthesis and antiproliferative activities of ottelione a analogues.

Tsai-Yuan Chang, Yun-Peng Tu, Win-Yin Wei, Hsiang Yu Chen, Chih-Shang Chen, Ying-Shuan E Lee, Jiann-Jyh Huang, Chin-Kang Sha

Abstract read
In one paragraph

Article in ACS medicinal chemistry letters, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tsai-Yuan ChangDepartment of Chemistry, National Tsing Hua University , Hsinchu, Taiwan, Republic of China.
Yun-Peng TuDepartment of Chemistry, National Tsing Hua University , Hsinchu, Taiwan, Republic of China.
Win-Yin WeiDevelopment Center for Biotechnology , No. 101, Lane 169, Kangning Street, Xizhi City, Taipei County, Taiwan 221, Republic of China.
Hsiang Yu ChenDevelopment Center for Biotechnology , No. 101, Lane 169, Kangning Street, Xizhi City, Taipei County, Taiwan 221, Republic of China.
Chih-Shang ChenDepartment of Applied Chemistry, National Chiayi University , No. 300, Syuefu Rd., Chiayi City, Taiwan 60004, Republic of China.
Ying-Shuan E LeeDevelopment Center for Biotechnology , No. 101, Lane 169, Kangning Street, Xizhi City, Taipei County, Taiwan 221, Republic of China.
Jiann-Jyh HuangDevelopment Center for Biotechnology , No. 101, Lane 169, Kangning Street, Xizhi City, Taipei County, Taiwan 221, Republic of China ; Department of Applied Chemistry, National Chiayi University , No. 300, Syuefu Rd., Chiayi City, Taiwan 60004, Republic of China.
Chin-Kang ShaDepartment of Chemistry, National Tsing Hua University , Hsinchu, Taiwan, Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Through the syntheses of its C-1 desvinyl, C-7 methylene, C-7 exocyclic ethylidene, and various C-3 phenylmethyl analogues, the structure-activity relationship of antimitotic ottelione A (4) against tubulin and various cancer cells was established. The results indicated that compound 4 was a colchicine-competitive inhibitor and that the C-1 vinyl group is unnecessary for its potency, whereas the C-7 exocyclic double bond is essential, possibly because of its irreversible interaction with tubulin. Further optimization of the substituents on the phenylmethyl group at the C-3 position generated compound 10g with a 3'-fluoro-4'-methoxyphenylmethyl substituent, which was 6-38-fold more active against MCF-7, NCI-H460, and COLO205 cancer cells relative to 4. Results from in vitro tubulin polymerization assay confirmed the potency of compounds 4, 10g, and 11a.

Indexed as

anticancerantimitoticmicrotubuleottelione Atubulin

Identifiers

PMID24900431
PMCPMC4025792

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.